Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
By J. Sapp, G. Wells, R. Parkash, W. Stevenson, L. Blier, J. Sarrazin, B. Thibault, Léna Rivard, L. Gula, P. Leong-Sit and 10 more. New England Journal of Medicine, 2016
734 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine
View Paper: https://www.semanticscholar.org/paper/3ff842ce40b1fdb6815e81c9a226e7abe19c512a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
Citations in the corpus
- 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. (2019, background): “Catheter ablation is recognized as a central treatment option for patients with ventricular arrhythmias who have received therapies from their ICDs, and in the context of failure or intolerance of antiarrhythmic drugs.(213,214) For ARVC, evidence from single-center and multicenter cohorts has demons”